The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology”
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
January 2026 in “Queensland University of Technology” Dietetic-led cognitive-behavioral therapy may improve treatment for adults with ARFID.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
21 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
21 citations
,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
3 citations
,
August 2024 in “Frontiers in Oncology” Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
December 2025 in “Canadian Urological Association Journal” Alternative therapies for men's health lack strong scientific support and need more research.
May 2026 in “Inflammopharmacology”
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
July 2023 in “JAAD International” Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
Baricitinib is more effective than methotrexate for severe alopecia areata.
1 citations
,
April 2017 in “Drugs & Therapy Perspectives” Use antiandrogens and other treatments for hair loss.
January 2026 in “Digital Repository (National Repository of Grey Literature)” Certain treatments, especially MZT1 and PRP2, effectively improve hair density and thickness in androgenetic alopecia.
June 2024 in “Journal of medicinal chemistry” A new AI-driven method shows promise for treating hair loss with a peptide-based drug.
35 citations
,
May 2012 in “Expert Opinion on Pharmacotherapy” The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
68 citations
,
May 2024 in “International Journal of Molecular Sciences” Personalized acne treatments and new therapies show promise for better results.